Results 31 to 40 of about 12,296,614 (200)

Liposomal Amphotericin B: A Cost-Outcome Analysis [PDF]

, 1994
Our objective in this study was to conduct a cost-outcome analysis of the use of liposomal amphotericin B in our institution, which is a tertiary care, adult, university-affiliated hospital.
Brunet, Anne-Marie, Toye, Baldwin W., Garber, Gary E., Tierney, Michael G., McLean, William M.   +4 more
core   +1 more source

Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil

Revista da Sociedade Brasileira de Medicina Tropical, 2019
INTRODUCTION: Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.
Tália Santana Machado de Assis, Ana Rabello, Gláucia Cota, Guilherme Loureiro Werneck, André Luís Ferreira de Azeredo-da-Silva   +4 more
doaj   +1 more source

HIV-associated disseminated histoplasmosis successfully treated with isavuconazole consolidation therapy

Medical Mycology Case Reports, 2020
A 30-year-old man with advanced HIV and disseminated histoplasmosis deteriorated after stepping down from intravenous liposomal amphotericin B to itraconazole.Therapeutic levels of itraconazole and posaconazole were not achieved, therefore liposomal ...
Andrea Mazzella, Neil R.H. Stone, Erica R.M. Pool, Ana García Mingo, Sorina Bolache, Chris Wood   +5 more
doaj   +1 more source

Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report

Revista da Sociedade Brasileira de Medicina Tropical, 2019
In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate.
Benivaldo Ramos Ferreira Terceiro, Tania Salgado de Souza Torraca, Frederico Pereira Bom Braga, Ana Cristina da Costa Martins, Lucia Regina Brahim, Mauricio Naoto Saheki, Luciana de Freitas Campos Miranda, Armando de Oliveira Schubach, Cláudia Maria Valete-Rosalino   +8 more
doaj   +1 more source

Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine

Medical Mycology Case Reports, 2014
A patient with Candida spondylitis failed two weeks of fluconazole combined with caspofungin, and the infection relapsed despite six weeks of liposomal amphotericin B followed by two months of fluconazole.
Line Storm, Karen R. Lausch, Maiken C. Arendrup, Klaus L. Mortensen, Eskild Petersen   +4 more
doaj   +1 more source

Using single-dose liposomal amphotericin B for cryptococcal meningitis induction therapy: nurse pearls and practical perspectives [version 1; peer review: 2 approved]

Wellcome Open Research
Background In Uganda where the burden of HIV-associated cryptococcal meningitis is high, conventional amphotericin B deoxycholate has been standard to manage patients with cryptococcal meningitis in research settings.
Richard Kwizera, Cynthia Ahimbisibwe, Jane Frances Ndyetukira, David B. Meya, Carol Namujju   +4 more
doaj   +1 more source

Liposomal Amphotericin B

Nippon Ishinkin Gakkai Zasshi, 2005
Liposomal amphotericin B (AmBisome) is a DDS (drug delivery system) formulation of amphotericin B (AMPH-B), and has been developed in an attempt to reduce the toxicity of AMPH-B while retaining its therapeutic efficacy. AMPH-B has been the "gold standard" of antifungal therapy over the past four decades.
openaire   +3 more sources

Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B [PDF]

, 2021
OBJECTIVES: Liposomal amphotericin B is widely used to treat life-threatening invasive fungal infections and has replaced conventional amphotericin B deoxycholate due to its more favourable toxicity profile. Despite the fact that liposomal amphotericin B
Daele, R. Van, Bruggemann, Roger J., Brüggemann, R.J.M., Spriet, Isabel, Van Daele, Ruth, Maertens, J., de Beer, Yvo, Aarnoutse, Rob, Maertens, Johan, Beer, Y. de, Wauters, J., Croes, S., Aarnoutse, R.E., Spriet, I., Croes, Sander, Wauters, Joost   +15 more
core   +1 more source

Noncovalent complexation of amphotericin-B with Poly(α-glutamic acid).

, 2013
A noncovalent complex of amphotericin B (AmB) and poly(α-glutamic acid) (PGA) was prepared to develop a safe and stable formulation for the treatment of leishmaniasis. The loading of AmB in the complex was in the range of ∼20-50%.
Croft, Simon L, Mohamed-Ahmed, Abeer HA, Simon L. Croft, Les, Karolina A, Karin Seifert, Seifert, Karin, Brocchini, Stephen, Stephen Brocchini, Abeer H. A. Mohamed-Ahmed, Karolina A. Les   +9 more
core   +1 more source

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. [PDF]

, 2022
BACKGROUND: Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)-related death in sub-Saharan Africa. Whether a treatment regimen that includes a single high dose of liposomal amphotericin B would be efficacious is not known ...
Leeme, Tshepo, Nuwagira, Edwin, Tugume, L, Hope, W, Meintjes, Graeme, Chen, Tao, Comins, Kyla, Hosseinipour, MC, Hlupeni, Admire, Chawinga, C, Singh, A, Lortholary, Olivier, Mwandumba, HC, Muzoora, Conrad, Jaffar, Shabbar, Kasibante, J., Jjunju, Samuel, Lalloo, David G, van Widenfelt, Erik, Mutata, C., Jjunju, S, Harrison, T. S., Lawrence, DS, Meya, David, Rutakingirwa, M. K., Lawrence, D. S., Jarvis, J. N., Hlupeni, A, Tugume, Lillian, Loyse, A., Harrison, Thomas S, Mutata, Constantine, Hosseinipour, M. C., Hope, William, Harrison, TS, Kagimu, Enock, Mpoza, E., Kasibante, John, Mosepele, Mosepele, Meintjes, G, Mosepele, M, Boulware, D. R., Kanyama, C., Boulware, David R, Van Widenfelt, E., Rutakingirwa, MK, Rhein, J., Youssouf, N, Comins, K, Mzinganjira, H., Mpoza, Edward, Mutata, C, Wang, D, Group, Ambition Study, Nuwagira, E., Chen, T., Hosseinipour, Mina C, Jarvis, Joseph, Lortholary, O, Boyer-Chammard, Timothée, Mwandumba, Henry, Youssouf, N., Jarvis, JN, Rhein, J, Lalloo, David, Muzoora, C., Mzinganjira, Henry, Siamisang, Keatlaretse, Lawrence, David, Rutakingirwa, Morris, Harrison, Thomas, Mosepele, M., Leeme, T, Siamisang, K., Hope, W., Meya, David B, Moyo, Melanie, Ssebambulidde, K, Moyo, M., Ndhlovu, CE, Comins, K., Lalloo, David; id_orcid, Molloy, Síle, Singh, Achita, Jjunju, S., Meya, D. B., Kagimu, E., Molloy, Si­le F, Moyo, M, Hosseinipour, Mina, Boyer-Chammard, T, Molloy, Síle F, Ssebambulidde, K., Singh, A., Kanyama, Cecilia, Ndhlovu, Chiratidzo E, Kasibante, J, Lalloo, DG, Ndhlovu, C. E., Rutakingirwa, Morris K, Schutz, C, Ssebambulidde, Kenneth, Tugume, L., Ndhlovu, Chiratidzo, Nuwagira, E, Ambition Study Group, Mwandumba, Henry C, Kagimu, E, Muzoora, C, Schutz, C., Boulware, DR, Loyse, Angela, Mzinganjira, H, Hlupeni, A., Jarvis, Joseph N, Kanyama, C, Meya, DB, Chen, T, Chawinga, Chimwemwe, Boyer-Chammard, T., Wang, Duolao, Lawrence, David S, Rhein, Joshua, Molloy, S. F., Siamisang, K, Boulware, David, van Widenfelt, E, Loyse, A, Meintjes, G., Leeme, T., Jaffar, S, Chawinga, C., Molloy, SF, Schutz, Charlotte, Mpoza, E, Youssouf, Nabila, Lortholary, O.   +136 more
core   +1 more source